Healthcare provider profile · identity verified

Thomas Emmanuel Hargest, MD, PHD

Family Practice · YORK, PA · NPI 1528082930

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	534	159
Levothyroxine Sodium	Levothyroxine Sodium	349	94
Lisinopril	Lisinopril	332	96
Amlodipine Besylate	Amlodipine Besylate	315	92
Rosuvastatin Calcium	Rosuvastatin Calcium	288	85
Losartan Potassium	Losartan Potassium	240	69
Simvastatin	Simvastatin	240	70
Metoprolol Succinate	Metoprolol Succinate	197	59
Pantoprazole Sodium	Pantoprazole Sodium	193	63
Metformin Hcl	Metformin Hcl	173	49
Metformin Hcl Er	Metformin Hcl	162	47
Zolpidem Tartrate	Zolpidem Tartrate	162	37
Furosemide	Furosemide	152	54
Gabapentin	Gabapentin	148	38
Meloxicam	Meloxicam	148	39
Omeprazole	Omeprazole	146	45
Lorazepam	Lorazepam	142	31
Hydrochlorothiazide	Hydrochlorothiazide	139	37
Tamsulosin Hcl	Tamsulosin Hcl	134	43
Metoprolol Tartrate	Metoprolol Tartrate	132	37
Tramadol Hcl	Tramadol Hcl	128	41
Glimepiride	Glimepiride	122	36
Valsartan	Valsartan	117	31
Eliquis	Apixaban	116	31
Alprazolam	Alprazolam	113	28
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	98	28
Allopurinol	Allopurinol	96	25
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	96	28
Pioglitazone Hcl	Pioglitazone Hcl	96	26
Pravastatin Sodium	Pravastatin Sodium	94	28
Clopidogrel	Clopidogrel Bisulfate	93	30
Shingrix	Varicella-Zoster Ge/As01b/Pf	92	71
Arexvy	Rsvpref3 Antigen/As01e/Pf	91	91
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	90	14
Clonazepam	Clonazepam	88	20
Atenolol	Atenolol	86	25
Albuterol Sulfate Hfa	Albuterol Sulfate	85	34
Ezetimibe	Ezetimibe	78	23
Methylprednisolone	Methylprednisolone	77	52
Finasteride	Finasteride	74	22
Meclizine Hcl	Meclizine Hcl	72	26
Sertraline Hcl	Sertraline Hcl	70	23
Aripiprazole	Aripiprazole	67	15
Citalopram Hbr	Citalopram Hydrobromide	67	18
Famotidine	Famotidine	65	23
Fluticasone Propionate	Fluticasone Propionate	65	18
Alendronate Sodium	Alendronate Sodium	63	15
Ozempic	Semaglutide	62	14
Potassium Chloride	Potassium Chloride	61	21
Azithromycin	Azithromycin	60	46
Escitalopram Oxalate	Escitalopram Oxalate	59	18
Fenofibrate	Fenofibrate	59	17
Jardiance	Empagliflozin	56	16
Oxycodone Hcl	Oxycodone Hcl	56	suppressed
Buspirone Hcl	Buspirone Hcl	55	12
Venlafaxine Hcl Er	Venlafaxine Hcl	54	14
Diclofenac Sodium	Diclofenac Sodium	53	19
Trazodone Hcl	Trazodone Hcl	53	14
Triamcinolone Acetonide	Triamcinolone Acetonide	52	28
Prednisone	Prednisone	51	35
Telmisartan	Telmisartan	50	13
Carvedilol	Carvedilol	47	15
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	47	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	45	13
Synthroid	Levothyroxine Sodium	44	12
Lansoprazole	Lansoprazole	43	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	43	11
Warfarin Sodium	Warfarin Sodium	43	suppressed
Valacyclovir	Valacyclovir Hcl	42	18
Celecoxib	Celecoxib	41	suppressed
Rybelsus	Semaglutide	41	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	39	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	39	suppressed
Risedronate Sodium	Risedronate Sodium	37	suppressed
Ventolin Hfa	Albuterol Sulfate	36	suppressed
Fluconazole	Fluconazole	35	12
Bupropion Hcl Sr	Bupropion Hcl	34	suppressed
Montelukast Sodium	Montelukast Sodium	34	13
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	33	25
Breo Ellipta	Fluticasone/Vilanterol	33	suppressed
Lovastatin	Lovastatin	33	suppressed
Mounjaro	Tirzepatide	32	suppressed
Nifedipine Er	Nifedipine	32	suppressed
Hydralazine Hcl	Hydralazine Hcl	31	11
Amoxicillin	Amoxicillin	29	22
Hydroxyzine Hcl	Hydroxyzine Hcl	29	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	29	suppressed
Paroxetine Hcl	Paroxetine Hcl	28	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	27	21
Januvia	Sitagliptin Phosphate	27	suppressed
Myrbetriq	Mirabegron	26	suppressed
Duloxetine Hcl	Duloxetine Hcl	25	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	25	suppressed
Memantine Hcl	Memantine Hcl	25	suppressed
Ropinirole Hcl	Ropinirole Hcl	25	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	24	suppressed
Gemfibrozil	Gemfibrozil	24	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	24	suppressed
Sucralfate	Sucralfate	24	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	24	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	23	23
Cephalexin	Cephalexin	23	15
Glipizide Er	Glipizide	23	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	23	21
Propranolol Hcl	Propranolol Hcl	23	suppressed
Ondansetron Hcl	Ondansetron Hcl	22	12
Bupropion Xl	Bupropion Hcl	21	suppressed
Donepezil Hcl	Donepezil Hcl	21	suppressed
Farxiga	Dapagliflozin Propanediol	21	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	21	suppressed
Naproxen	Naproxen	20	suppressed
Pregabalin	Pregabalin	20	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	20	suppressed
Nystatin	Nystatin	19	12
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	18	suppressed
Estradiol	Estradiol	18	suppressed
Mirtazapine	Mirtazapine	18	suppressed
Novolog Flexpen	Insulin Aspart	18	suppressed
Spironolactone	Spironolactone	18	suppressed
Terazosin Hcl	Terazosin Hcl	18	suppressed
Diazepam	Diazepam	17	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	17	suppressed
Glyxambi	Empagliflozin/Linagliptin	17	suppressed
Baclofen	Baclofen	16	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	16	suppressed
Nitroglycerin	Nitroglycerin	16	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	16	suppressed
Prolia	Denosumab	16	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	16	suppressed
Ultra-Fine Micro Pen Needle	Pen Needle, Diabetic	16	suppressed
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	15	suppressed
Glipizide	Glipizide	15	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	15	suppressed
Repatha Sureclick	Evolocumab	15	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	15	12
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	15	suppressed
Xarelto	Rivaroxaban	15	suppressed
Gemtesa	Vibegron	14	suppressed
Telmisartan-Hydrochlorothiazid	Telmisartan/Hydrochlorothiazid	14	suppressed
Bumetanide	Bumetanide	13	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	13	suppressed
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	13	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	13	suppressed
Tizanidine Hcl	Tizanidine Hcl	13	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	12	suppressed
Ibandronate Sodium	Ibandronate Sodium	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Promethazine Hcl	Promethazine Hcl	12	suppressed
Topiramate	Topiramate	12	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed
Hydrocortisone	Hydrocortisone	11	suppressed
Lamotrigine	Lamotrigine	11	suppressed
Levofloxacin	Levofloxacin	11	11
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	11	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error